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Abstract Ceramide is an important lipid messenger involved in
mediating a variety of cell functions including apoptosis. In this
study, we show that antisense bax inhibits cytochrome c release,
poly(ADP-ribose)polymerase cleavage and cell death induced by
ceramide in HL-60 cells. In addition, ceramide induces
translocation of Bax to mitochondria. The addition of the broad
spectrum caspase inhibitor zVAD-fmk prevented ceramide-
induced apoptotic cell death but did not inhibit translocation of
Bax and mitochondrial cytochrome c release. Furthermore,
ceramide inhibits the expression of the antiapoptotic protein Bcl-
xL with an increase in the ratio of Bax to Bcl-xL. These data
provide direct evidence that Bax plays an important role in
regulating ceramide-induced apoptosis. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Ceramide is an important lipid messenger involved in me-
diating a variety of cell functions including apoptosis, cell
cycle arrest and cell senescence [1^3]. Apoptosis induced by
a variety of inducers such as tumor necrosis factor-K (TNF-
K), Fas ligation and chemotherapeutic agents and environ-
mental stresses is associated with the hydrolysis of sphingo-
myelin accompanied by the accumulation of ceramide [4^7].
Moreover, exogenous cell permeable ceramide and endoge-
nous ceramide generated by sphingomyelinase activation spe-
ci¢cally induce apoptosis in many di¡erent cell types. Ceram-
ide is therefore considered to be a common mediator of
apoptotic mechanisms. However, signal transduction path-
ways mediating ceramide-induced apoptosis are largely un-
known. Present knowledge indicates that a ceramide-mediated
apoptotic pathway includes cytochrome c release and the ac-
tivation of several caspases, cleavage of speci¢c substrates by
caspase which lead to DNA fragmentation [8^12]. But how
the caspase activation and cytochrome c release occur during
ceramide-induced apoptosis is not clear.
Apoptotic stimuli such as activation of cell surface recep-
tors or environmental stress can induce cytochrome c release
from mitochondria. Once released, cytochrome c binds to
Apaf-1 and activates caspase-9 in the presence of dATP [13^
15]. The activated caspase-9 leads to the activation of down-
stream e¡ector caspase, such as caspase-3, which cleaves a
number of cellular proteins to execute cell death. It has re-
cently been proposed that in receptor-mediated apoptosis,
Bid, activated by caspase-8, is translocated to the mitochon-
dria and induces the release of cytochrome c, whereas in
chemical-induced apoptosis, cytochrome c release is caspase-
independent and is not mediated by cleavage of Bid [16^18].
Bax is a proapoptotic members of the Bcl-2 family that
resides in the cytosol and translocates to mitochondria upon
induction of apoptosis [19^21]. Recently, Bax has been shown
to induce cytochrome c release and caspase activation in vivo
and in vitro [20,22]. In contrast, antiapoptotic Bcl-2 and Bcl-
xL can block cytochrome c release in cells undergoing apo-
ptosis [22^24]. The antiapoptotic Bcl-2 family reside on the
outer mitochondrial membrane and can inhibit apoptosis by
many mechanisms such as homo- or heterodimerization with
other family members, maintenance of normal mitochondrial
membrane resulting in the prevention of cytochrome c release
and subsequent caspase activation. Recent studies have shown
that Bcl-xL abolishes apoptosis, caspase-3 activity, and release
of cytochrome c induced by ceramide [12,25]. At present, it is
still not clear how ceramide acts on mitochondria.
In this report, we examined pathways downstream of cer-
amide, with particular focus on the ability of Bax to induce
the release of cytochrome c and apoptosis, and we evaluated
the relationships between mitochondrial dysfunction and cas-
pase activation. By using a speci¢c bax antisense oligonucleo-
tide, we demonstrate the important functional role of Bax in
ceramide-induced apoptosis. We show that antisense bax in-
hibits cytochrome c release, poly(ADP-ribose)polymerase
(PARP) cleavage and cell death. In addition, ceramide induces
translocation of Bax to mitochondria and increases the ratio
of Bax to Bcl-xL. Our ¢ndings suggest that Bax plays an
important role in regulating the apoptotic process upstream
of cytochrome c release induced by ceramide.
2. Materials and methods
2.1. Materials
C6-ceramide was obtained from Sigma. Lipofectamine was obtained
from Life Technologies. Fetal bovine serum was from Gibco BRL,
ECL kit from Amersham Pharmacia, caspase-3, 8, 9 substrates from
Biomol, and Hoechst 33258 from Molecular Probes. Antibody to
cytochrome c was from Pharmingen. Antibodies to Bax, Bcl-2, Bcl-
xL and HRP-conjugated secondary antibody were from Santa Cruz
Biotechnology. zVAD-fmk was from Enzyme System Products.
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2.2. Cell viability and internucleosomal DNA fragmentation
HL-60 cells were washed with serum-free RPMI. Ceramide, zVAD-
fmk or vehicle was diluted into serum-free RPMI at the indicated
concentrations. Cell viability and DNA fragmentation were analyzed
as described previously [26]. For C6-ceramide-induced apoptosis, HL-
60 cells were maintained in serum-free RPMI for 24 h before experi-
ments. Staining nuclei with Hoechst 33258 was performed as de-
scribed previously [26].
2.3. Oligonucleotide treatment
HL-60 cells were cultured at 5U105 cells per ml in the presence or
absence of ceramide and/or Bax antisense oligodeoxynucleotides for
the indicated times in complete culture medium (RPMI 1640 supple-
mented with 10% fetal bovine serum). Bax antisense and scrambled
oligodeoxynucleotides with a natural phosphodiester backbone were
synthesized by Bioneer (Chungbuk, South Korea). Sequences used
were according to previously published work [27]: antisense Bax, 5P-
TCG ATC CTG GAT GAA ACC CT-3P and 5P-TCC CCC CCC
ATT CGC CCT GC-3P and scrambled Bax, 5P-TCA GTC CTG
GTA GAA CAC CT-3P and 5P-CTC CCC CCA CTT CGC CTC
GC-3P. Inhibition of Bax protein expression was achieved by using
a mixture of the two antisense molecules, both at a ¢nal concentration
of 1 WM.
2.4. Subcellular fractionation
The basic methodology for the preparation of mitochondria and
cytosol fractions was modi¢ed from a previous report [28]. Brie£y,
HL-60 cells (3U106) at the end of the treatment were harvested and
washed with ice-cold PBS. Cells were resuspended in 500 Wl of bu¡er
A (20 mM HEPES^KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM
sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol) contain-
ing 250 mM sucrose and a mixture of protease inhibitors (1 mM
PMSF, 1% aprotinin, 1 mM leupeptin, 1 Wg/ml chymostatin). To
lyse the cells, the cell suspension was passed ¢ve times through a
26-gauge needle ¢tted to a syringe. Unbroken cells, large plasma
membrane pieces, and nuclei were removed by centrifuging the homo-
genates at 1000Ug at 4‡C for 10 min. The resulting supernatant was
subjected to 10 000Ug centrifugation at 4‡C for 20 min. The pellet
fraction (i.e. mitochondria) was ¢rst washed with the above bu¡er A
containing sucrose and then solubilized in 50 Wl of TNC bu¡er
(10 mM Tris^acetate, pH 8.0, 0.5% NP-40, 5 mM CaCl2). The super-
natant was recentrifuged at 100 000Ug (4‡C, 1 h) to generate cytosol.
2.5. Western blot analysis
Cells were solubilized with ice-cold lysis bu¡er containing 1% Tri-
ton X-100, 50 mM NaCl, 25 mM HEPES (pH 7.4), 1 mM EDTA,
1 mM EGTA, 1 mM phenylmethylsulfonyl £uoride, and 10 Wg/ml
leupeptin. Insoluble materials were removed by centrifugation at
10 000Ug for 10 min. Extracted proteins (50 Wg/well) were separated
by sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) on 12% polyacrylamide gels, and were electrophoretically
transferred onto Immobilon-P membrane. Blocking was performed
in Tris-bu¡ered saline containing 5% skimmed milk powder and
0.1% Tween-20. The membranes were probed with antibodies against
PARP, cytochrome c, Bcl-2, Bax, Bcl-xL or actin. Detection was
performed with ECL system. Protein content was determined with
the Bradford method using bovine serum albumin as a standard.
2.6. Measurement of caspase activity
Cell lysates were incubated with the colorimetric substrates:
DEVD-pNA (caspase-3) or IETD-pNA (caspase-8) to measure cas-
pase activity according to the protocol suggested by the manufacturer.
Reactions were assembled in microtiter plate wells by adding 160 Wl of
bu¡er B (100 mM HEPES (pH 7.5), 20% (v/v) glycerol, 5 mM DTT,
and 0.5 mM EDTA) containing 100 WM substrate to wells containing
50 Wg of cytosolic protein in 40 Wl of bu¡er A. Plates were incubated
at 37‡C for 1 h. Release of free pNA, which absorbs at 405 nm, was
monitored continuously.
3. Results
3.1. Cell death, but not cytochrome c release is prevented by
zVAD-fmk in ceramide-treated HL-60 cells
To elucidate the role of caspases in ceramide-induced apo-
ptosis, HL-60 cells were treated with caspase inhibitor, and we
investigate the e¡ects of apoptotic signaling events, including
cytochrome c release during ceramide-induced apoptosis.
Induction of apoptosis by ceramide was con¢rmed by de-
tecting DNA fragmentation in HL-60 cells. In parallel, cyto-
chrome c release and caspase activation were determined. In
agreement with other cell lines [11,12], ceramide induced in-
ternucleosomal DNA fragmentation, cytochrome c release
from mitochondria and subsequent activation of caspase-3
(Fig. 1). However, activation of caspase-8 occurred at a late
time after ceramide treatment (Fig. 1C). Cells treated with
ceramide exhibited activation of caspase-3 after 12 h while
caspase-8 was activated at 24 h after ceramide treatment.
This observation indicates that both caspases act as down-
stream caspases. DNA fragmentation induced by ceramide
was inhibited by the broad caspase inhibitor benzoyloxycar-
Fig. 1. Cell death, but not cytochrome c release is prevented by
zVAD-fmk in ceramide-treated HL-60 cells. HL-60 cells were
treated with 20 WM C6-ceramide in the presence or absence of
zVAD-fmk (50 WM). A: DNA extracted from the cells was sub-
jected to conventional agarose gel electrophoresis. B: Cytosolic and
mitochondrial fractions were prepared at the indicated times, sepa-
rated by 12% SDS^PAGE, and immunoblotted with a mouse anti-
cytochrome c antibody. C: At the indicated times, samples of cell
extracts were assessed for their ability to hydrolyze the peptides
DEVD-pNA and IETD-pNA. Results shown are representatives of
three separate experiments.
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bonyl-VAD-£uoromethylketone (zVAD-fmk) (Fig. 1A),
whereas cytochrome c release was not a¡ected by zVAD-
fmk (Fig. 1B). Present results show that zVAD-fmk has no
e¡ect upstream of cytochrome c release but blocks cell death,
indicating downstream caspases are required for ceramide-
mediated cell death in HL-60 cells.
3.2. Bax is required for cytochrome c release in
ceramide-induced apoptosis
The experiments described above indicate that ceramide-in-
duced cytochrome c release in HL-60 cells is caspase-inde-
pendent. Recent reports have shown that Bax can directly
induce cytochrome c release from mitochondria without re-
quirement for caspases [22]. Induction of cytochrome c release
from mitochondria occurs via caspase-8-mediated cleavage of
Bid and (or) Bax mitochondrial translocation [17,19,20]. Since
ceramide-induced caspase-8 activation was observed after cy-
tochrome c release (Fig. 1), we analyzed whether Bax is in-
volved in cytochrome c release. To determine if Bax is essen-
tial for cytochrome c release in ceramide-mediated apoptosis
in HL-60 cells, we used Bax antisense oligodeoxynucleotides
to speci¢cally decrease intracellular Bax levels. Cells exposed
to 1 WM of Bax antisense oligodeoxynucleotides for 24 h ex-
pressed markedly reduced Bax protein levels (Fig. 2A). As
assessed by trypan blue or Hoechst dye staining, Bax anti-
sense inhibited cell death and prevented nuclear DNA frag-
mentation (Fig. 2), indicating that Bax is required for medi-
ating apoptosis induced by ceramide. Furthermore, Bax
antisense prevented ceramide-induced cytochrome c release
and PARP cleavage (Fig. 3). These results indicate that Bax
promotes apoptotic cell death and induces cytochrome c re-
lease downstream of ceramide.
3.3. Ceramide induces downregulation of Bcl-xL protein and
alteration of Bax/Bcl-xL ratio
Bax may play a crucial role in the apoptotic process via a
number of di¡erent mechanisms. For example, Bcl-2 or Bcl-
xL counteracts the e¡ect of Bax by forming heterodimers with
it. Previous studies have shown that the ratio between pro-
apoptotic and antiapoptotic Bcl-2 families plays a major role
in susceptibility of cells to apoptotic stimuli [29,30].
To determine the mechanisms by which ceramide causes
Bax-dependent apoptosis, we investigated the expression of
antiapoptotic and proapoptotic members of the Bcl-2 family
in ceramide-treated cells. As shown in Fig. 4, Bcl-2 level was
not changed by ceramide treatment, but the expression of the
Bcl-xL protein was substantially reduced whereas the level of
Fig. 2. Bax antisense reduces cell death induced by ceramide. HL-60
cells were incubated with 1 WM of Bax antisense (as) or scrambled
oligonucleotides (sc). A: After a recovery period of 24 h, Bax pro-
tein levels were determined by Western blot. The Bax band migrates
at V23 kDa. B: After treatment with C6-ceramide (20 WM), cell vi-
ability was determined at the indicated times. C: Fluorescence pho-
tomicrographs of Hoechst 33258 staining of HL-60 cells treated
with C6-ceramide (20 WM, 24 h) in the presence of Bax antisense or
scrambled oligonucleotides.
Fig. 3. Bax is required for cytochrome c release in ceramide-induced
cell death. HL-60 cells were incubated with 1 WM of Bax antisense
or scrambled oligonucleotides. After a recovery period of 24 h, cells
were treated with C6-ceramide and collected at the indicated times.
Cells were fractionated and equal amounts of cytosolic and mito-
chondrial protein were loaded, separated by SDS^PAGE, and im-
munoblotted with an anti-cytochrome c antibody or anti-PARP
antibody.
Fig. 4. Ceramide induces alteration in the Bax/Bcl-xL ratio. HL-60
cells were treated with 20 WM C6-ceramide for the indicated time
points. Equal amounts of cell lysates were separated by SDS^
PAGE, followed by Western blot with a rabbit anti-Bax antibody,
an anti-Bcl-xL antibody, or anti-Bcl-2 antibody.
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Bax was slightly increased by ceramide. Downregulation of
Bcl-xL was detected 24 h after treatment with ceramide
(Fig. 4), which is in accordance with the time course of cas-
pase-8 activation (Fig. 1).
3.4. Ceramide induces caspase-independent alteration in
subcellular distribution of Bax
Since Bax has been shown to induce cytochrome c release
from mitochondria to the cytosol in conjunction with apopto-
sis in several cell lines and translocation of Bax to mitochon-
drial outer membrane is a primary event in triggering mito-
chondrial function [20], we examined the subcellular
distribution of Bax after ceramide treatment of HL-60 cells.
As shown in Fig. 5, Bax translocation from the cytosol to the
mitochondria occurred within 6 h after treatment with ceram-
ide in HL-60 cells. Bax translocation was accompanied by
cytochrome c release and PARP cleavage (Figs. 1 and 5).
Pretreatment of HL-60 cells with zVAD-fmk did not block
Bax mitochondrial translocation (Fig. 5). Therefore, Bax
translocation is caspase-independent and downstream caspase
is required for cell death in the ceramide-mediated apoptosis.
4. Discussion
Although numerous studies document mitochondria-depen-
dent cell death induced by ceramide, the molecular ordering
of ceramide signaling remains unclear. In this study we have
shown that Bax mediates mitochondrial cytochrome c release,
and caspase activation during ceramide-induced apoptosis in
HL-60 cells. Of particular interest, ceramide induces subcellu-
lar redistribution of Bax, which was associated with cyto-
chrome c release from the mitochondria independently of cas-
pase activation. We also found that caspase activation is
required for signaling events downstream of mitochondria,
such as PARP cleavage and DNA fragmentation in ceram-
ide-induced cell death.
Bax has been known to cause cytochrome c release from
mitochondria and caspase activation in cell-free extracts and
in cells treated with apoptosis-inducing agents [22,24]. In ad-
dition, Bax translocates from its predominantly cytoplasmic
location to the mitochondria upon apoptosis induction
[19,20]. Bcl-2 and Bcl-xL have been shown to inhibit Bax
translocation, cytochrome c release and caspase activation
induced by Fas or other apoptotic inducing agents [20,22,23].
Several recent reports have shown that overexpressing Bcl-2
or Bcl-xL inhibits ceramide accumulation during apoptosis
induced by chemotherapeutic agents, irradiation, or hypoxia.
In contrast, Bax had no e¡ect on ceramide formation during
etoposide-induced apoptosis, but enhanced etoposide-induced
apoptosis through acceleration of cytochrome c release and
caspases activation [8,12,25]. These results indicate that Bax
may act downstream or independent of ceramide to directly
activate the release of cytochrome c. To clarify the role of Bax
in the regulation of ceramide-induced apoptosis, we used Bax
antisense oligodeoxynucleotides to decrease intracellular Bax
levels. We demonstrated that treatment of HL-60 cells with
Bax antisense prevented ceramide-induced apoptosis, cyto-
chrome c release and PARP cleavage. Our data suggest that
Bax acts downstream of ceramide to induce cytochrome c
release, providing direct evidence for a role of Bax in the
apoptotic pathway mediated by ceramide. The mechanism
by which ceramide causes Bax-dependent apoptosis has not
yet been determined. Recent reports suggest that alterations in
the ratio between proapoptotic and antiapoptotic members of
the Bcl-2 family, rather than the absolute expression level of
any single Bcl-2 member, can determine apoptotic sensitivity
[29,30], which would interfere with the availability and trans-
location of the Bax protein from the cytoplasm to the mito-
chondria. It was also reported that overexpression of Bcl-2 or
Bcl-xL protected against ceramide-induced apoptosis [25].
Previously, we reported ceramide increased Bax/Bcl-2 ratio
in HL-60 cells [31]. Here, we observed decreased Bcl-xL ex-
pression with an increase in the Bax/Bcl-xL ratio in ceramide-
treated HL-60 cells. Therefore, it is suggested that the e¡ect of
Bax on ceramide-mediated apoptosis may be related to the
decreased levels of proapoptotic members of the Bcl-2 family,
thereby weakening the death-protecting signaling during apo-
ptosis. Since Bcl-xL and Bax act antagonistically in the regu-
lation of apoptosis, the ratio of Bax and Bcl-xL protein levels
is important for cells undergoing apoptosis. Recent data sug-
gest that ceramide could signal mitochondrial apoptosis by
inhibiting the protein kinase Akt [26,32], which phosphory-
lates Bad. Phosphorylation of Bad via growth factor receptor
signaling and the Akt kinase releases Bcl-xL to target mito-
chondria. Thus, inhibition of Akt by ceramide leads to inhi-
bition of antiapoptotic protein Bcl-xL by Bad. Based on these
observations, it is postulated that ceramide may induce apo-
ptosis by increasing proapoptotic signaling and decreasing
antiapoptotic signaling, leading to disruption of the balance
of antiapoptotic and proapoptotic signaling within the cell.
In this study, we detected caspase-independent mitochon-
drial Bax translocation and cytosolic release of cytochrome c,
and observed caspase-dependent PARP cleavage and DNA
fragmentation by ceramide, indicating downstream caspase
is required for ceramide-induced apoptosis. These ¢ndings
are similar to reports that caspase inhibitors had no e¡ect
on Bax-induced cytochrome c release, but prevented cleavage
of nuclear substrates and DNA fragmentation [22]. In addi-
tion to activation of caspase-3 in ceramide-treated cells, cas-
pase-8 activation was also observed. Caspase-8 has been
shown to cleave Bid and the cleaved Bid is reported to be
more e⁄cient for triggering the oligomerization and translo-
cation of Bax into mitochondrial membrane [33]. Many re-
Fig. 5. Ceramide induces caspase-independent Bax translocation
from cytosol to mitochondria. HL-60 cells were preincubated with
50 WM of zVAD-fmk for 1 h and then treated with C6-ceramide (20
WM) for the indicated times. Cells were fractionated and equal
amounts of cytosolic and mitochondrial protein were loaded, sepa-
rated by SDS^PAGE and immunoblotted with an anti-Bax antibody
or anti-PARP antibody.
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ports indicate that ceramide formation in response to various
death triggers is mediated by caspase-8 activation [8,9,12].
These results indicate that caspase-8 is positioned upstream
of ceramide or between ceramide and Bax in the apoptotic
signaling pathway. However, we observed caspase-8 activa-
tion in response to ceramide occurred after caspase-3 activa-
tion implying that caspase-8 acts as a downstream caspase in
ceramide-induced apoptosis. This discrepancy may be ex-
plained by the di¡erential timing of caspase-8 activation be-
tween receptor-mediated and non-receptor-induced apoptosis.
It is demonstrated that caspase-8 is the most upstream caspase
for the induction of receptor-mediated apoptosis, but may be
activated downstream of cytochrome c release in non-receptor
forms of apoptosis [34]. It is also reported that Bcl-xL blocked
TNF-K-induced caspase-8 activation [35]. When comparing
the time course for activation of caspase-8 with expression
of Bcl-xL protein, it is suggested that decreases in Bcl-xL
levels could trigger caspase-8 activation downstream of mito-
chondria.
In summary, ceramide mediates apoptosis of HL-60 cells
through mitochondrial signaling which involves translocation
of Bax to mitochondria where it promotes the release of cy-
tochrome c. Our results contribute to the ordering of events
during ceramide-induced apoptosis, by demonstrating that
Bax is responsible for cytochrome c release and caspase-3
activation. In addition, Bax translocation is independent of
caspase activation and precedes cytochrome c release from
the mitochondria. Further studies will be required to identify
the speci¢c signals that induce mitochondrial Bax transloca-
tion by ceramide.
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